|
21st Annual Meeting of the Consortium of Multiple Sclerosis Centers New Directions in Pain Management for Patients with Multiple SclerosisWashington, DC / May 30-June 2, 2007 Washington, DC - Multiple sclerosis (MS) is a debilitating disease of the central nervous system and is the most common neurological disease affecting young adults in Canada today. An estimated 50,000 Canadian men and women currently have the disease. Each day, approximately three more people—most often between the ages of 20 and 40 years—are diagnosed with MS. A common symptom is chronic neuropathic or nerve pain, which occurs in about half of people with MS. However, MS pain is often poorly (...) Read more... Attached to this page : 28th Annual Conference of the Canadian Pain Society Management of Central Neuropathic Pain, Fibromyalgia and Chronic Allodynia: Examining Modulation of the Endocannabinoid SystemVictoria, British Columbia / May 27-30, 2008 Victoria - The discovery of the physiological functions of the endocannabinoid system in the central and peripheral nervous systems and peripheral organs has created opportunities to develop and study new treatment alternatives in a variety of pain states. At this year’s Canadian Pain Society conference, experts from the field of pain medicine presented new and updated findings on central neuropathic pain (CNP), fibromyalgia and chronic allodynia treated with an endocannabinoid system (...) Read more... Attached to this page : MEDICAL OPTIONS in Neuropathic Pain Defining Neuropathic Pain and Optimizing Treatment Approaches - Reviews from published literatureDecember 2008 Mechanisms of Action Guide Rational Choice of Therapy in Neuropathic Pain
Attached to this page : National Oncology Pharmacy Symposium 2008 Prevention and Management of Chemotherapy-induced Nausea and VomitingCalgary, Alberta / October 17-19, 2008 Calgary - Chemotherapy-induced nausea and vomiting (CINV) is a troublesome side effect of many cancer therapies. It affects almost all chemotherapy patients, some to the point where they discontinue their chemotherapy rather than suffer this distressing and debilitating condition. Clinicians often underestimate the risk of CINV, particularly the delayed form, which does not manifest itself until a day or more post-therapy. Consensus guidelines by the Multinational Association of Supportive (...) Read more... Attached to this page : |
